References
- Mac Manus MP, Matthews JP, Wada M, Wirth A, Worotniuk V, Ball DL. Unexpected long-term survival after low-dose palliative radiotherapy for non-small cell lung cancer. Cancer 2006;106:1110–6.
- Penland SK, Socinski MA. Management on unresectable stage III non-small cell lung cancer: the role of combined chemoradiation. Semin Radiat Oncol 2004;14:326–4.
- Choudhury A, Palma M, Mellstedt H. The future of cancer vaccines for non-small-cell lung cancer: ongoing trials. Clin Lung Cancer 2008;9Suppl 1:S37–44.
- Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, . Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008;112(6):2261–71.
- Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005;11:181–7.
- Zhang YS, Yuan FJ, Jia GF, Zhang JF, Hu LY, Huang L, . CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R.World. Gastroenterol 2005;11:3339–45.
- Ren X, Yu J, Liu H, Zhang P, An X, Zhang N, . Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients. Cancer Biotherapy & Radiopharmaceuticals 2006;21(1):22–33.
- Märten A, Ziske C, Schöttker B, Renoth S, Weineck S, Buttgereit P, . Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother 2001;24(6):502–10.
- Gallimore A, Godkin A. Regulatory T cells and tumour immunity - observations in mice and men. Immunology 2008;123(2):157–63.
- Parmar S, Platanias LC. Interferons: mechanisms of action and clinical applications. Curr Opin Oncol 2003;15(6):431–9.
- Thomas Calzascia, Marc Pellegrini, Håkan Hall, Sabbagh L, Ono N, Elford AR, . TNF-αis critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest 2007 December 3;117(12):3833–45.
- Gorbachev AV, Kobayashi H, Kudo D, Tannenbaum CS, Finke JH, Shu S, . CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J Immunol 2007;178(4):2278–86.
- Wahl SM, Wen J, Moutsopoulos N. TGF-beta: a mobile purveyor of immune privilege. Immunol 2006;213:213–27.
- Galliher AJ, Neil JR, Schiemann WP. Role of transforming growth factor-beta in cancer progression. Future Oncol 2006;2(6):743–63.
- Lewis AM, Varghese S, Xu H, H Richard Alexander. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 2006;4:48–59.
- Smith DR, Polverini PJ, Kunkel SL, Orringer MB, Whyte RI, Burdick MD, . Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 1994;179(5):1409–15.
- Heidemann J, Ogawa H, Dwinell MB, Rafiee P, Maaser C, Gockel HR, . Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem 2003;278(10):8508–15.
- Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, . Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000;6(8):3282–9.
- Ohta M, Kitadai Y, Tanaka S, Yoshihara M, Yasui W, Mukaida N, . Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer 2002;102(3):220–4.
- Kuroda T, Kitadai Y, Tanaka S, Yang X, Mukaida N, Yoshihara M, . Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin Cancer Res 2005;11(21):7629–36.
- Kiguchi T, Niiya K, Shibakura M, Miyazono T, Shinagawa K, Ishimaru F, . Induction of urokinase-type plasminogen activator by the anthracycline antibiotic in human RC-K8 lymphoma and H69 lung-carcinoma cells. Int J Cancer 2001;93(6):792–7.